Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3761721010 | Calcium carbonate 800 mg and famotidine 10 mg and magnesium hydroxide 165 mg chewable tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3761722015 | Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
2574717015 | Calcium carbonate 800mg/famotidine 10mg/magnesium hydroxide 165mg chewable tablet (product) | en | Fully specified name | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
2574717015 | Calcium carbonate 800mg/famotidine 10mg/magnesium hydroxide 165mg chewable tablet (product) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
2578114013 | Calcium carbonate 800mg/famotidine 10mg/magnesium hydroxide 165mg chewable tablet | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
2578114013 | Calcium carbonate 800mg/famotidine 10mg/magnesium hydroxide 165mg chewable tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3761721010 | Calcium carbonate 800 mg and famotidine 10 mg and magnesium hydroxide 165 mg chewable tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
3761722015 | Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Is a | Calcium carbonate + famotidine + magensium hydroxide (product) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Laxative | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Magnesium | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Trace element supplementation | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Famotidine (substance) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Magnesium hydroxide | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Magnesium-based antacid | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. | Calcium carbonate | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has manufactured dose form | A solid single-dose preparation obtained by compressing uniform volumes of particulate solids or by extrusion or moulding. Tablets may be single layer tablets resulting from a single compression of particles and or multilayer tablets consisting of concentric or parallel layers obtained by successive compressions of particles of different composition. | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has manufactured dose form | Conventional release oral tablet (dose form) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Is a | Famotidine-containing product in oral dose form | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has manufactured dose form | Conventional release chewable tablet (dose form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Is a | Product containing calcium carbonate in oral dose form (medicinal product form) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Is a | TEMPORARY parent for CDs that are not updated | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Count of base of active ingredient | trois | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Plays role | Laxative therapeutic role (role) | false | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator value | un | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator unit (attribute) | mg | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Is a | Product containing only calcium carbonate and famotidine and magnesium hydroxide in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | ||
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has basis of strength substance (attribute) | Magnesium hydroxide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has precise active ingredient | Magnesium hydroxide | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has precise active ingredient | Famotidine (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator value | dix | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has precise active ingredient | Calcium carbonate | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has basis of strength substance (attribute) | Famotidine (substance) | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 1 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has basis of strength substance (attribute) | Calcium carbonate | true | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator value | 165 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 3 | |
Product containing precisely calcium carbonate 800 milligram and famotidine 10 milligram and magnesium hydroxide 165 milligram/1 each conventional release chewable tablet (clinical drug) | Has presentation strength numerator value | 800 | false | Inferred relationship | Existential restriction modifier (core metadata concept) | 2 |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets